GlassScriptPhysician profile
Bunja Rungruang
NPI 1356547624
$3,109.73
in general payments reported to CMS, 2019-2025
51 companies · $451 in 2025
The $451 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $200 · 2021: $203 · 2022: $498 · 2023: $473 · 2024: $735 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504 · Travel and Lodging: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.33 |
| Travel and Lodging | $154.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $343.38 | 2019-2024 | |
| Intuitive Surgical, INC. | $293.60 | 2019-2025 | |
| Glaxosmithkline, LLC. | $218.51 | 2021-2024 | Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $188.32 | 2020-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $165.06 | 2019-2025 | Lynparza, Keytruda |
| Eisai INC. | $143.94 | 2019-2024 | |
| Janssen Biotech, INC. | $129.92 | 2019-2023 | |
| Clovis Oncology, INC. | $125.19 | 2019 | |
| Biotissue Holdings INC. | $118.20 | 2024 | |
| Pfizer INC. | $116.38 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.93 | 2024-2025 | Alunbrig, Ninlaro |
| Lsi Solutions INC | $71.43 | 2023 | Fornisee |
| Baxter Healthcare | $67.66 | 2020-2022 | |
| Abbvie INC. | $65.37 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.50 | 2019-2023 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bunja Rungruang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.